BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 11157027)

  • 1. Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group Study.
    Gaynor ER; Unger JM; Miller TP; Grogan TM; White LA; Mills GM; Balcerzak SP; Varterasian M; LeBlanc M; Fisher RI
    J Clin Oncol; 2001 Feb; 19(3):750-5. PubMed ID: 11157027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349).
    Blayney DW; LeBlanc ML; Grogan T; Gaynor ER; Chapman RA; Spiridonidis CH; Taylor SA; Bearman SI; Miller TP; Fisher RI;
    J Clin Oncol; 2003 Jul; 21(13):2466-73. PubMed ID: 12829664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
    Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
    Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
    Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
    N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505.
    Itoh K; Ohtsu T; Fukuda H; Sasaki Y; Ogura M; Morishima Y; Chou T; Aikawa K; Uike N; Mizorogi F; Ohno T; Ikeda S; Sai T; Taniwaki M; Kawano F; Niimi M; Hotta T; Shimoyama M; Tobinai K;
    Ann Oncol; 2002 Sep; 13(9):1347-55. PubMed ID: 12196359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255. Cancer and Leukemia Group B.
    Lichtman SM; Niedzwiecki D; Barcos M; Carlisle TL; Cooper MR; Johnson JL; Peterson BA
    Ann Oncol; 2000 Sep; 11(9):1141-6. PubMed ID: 11061609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.
    Gómez H; Mas L; Casanova L; Pen DL; Santillana S; Valdivia S; Otero J; Rodriguez W; Carracedo C; Vallejos C
    J Clin Oncol; 1998 Jul; 16(7):2352-8. PubMed ID: 9667250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study.
    Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
    Ann Oncol; 1994; 5 Suppl 2():91-5. PubMed ID: 7515652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas.
    Miller TP; Dana BW; Weick JK; Jones SE; Coltman CA; Dahlberg S; Fisher RI
    Semin Hematol; 1988 Apr; 25(2 Suppl 2):17-22. PubMed ID: 2456619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.
    Press OW; Unger JM; Braziel RM; Maloney DG; Miller TP; Leblanc M; Fisher RI;
    J Clin Oncol; 2006 Sep; 24(25):4143-9. PubMed ID: 16896003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous infusion of vincristine-doxorubicin with bolus of dexamethasone(VAD) alternated with CHEP in the treatment of patients over 60 years old with aggressive non-Hodgkin's lymphoma.
    Cartron G; Voillat L; Desablens B; Le Maignan C; Milpied N; Foussard C; Dugay J; Maakaroun A; De Muret A; Colombat P;
    Leuk Lymphoma; 2001 Feb; 40(5-6):529-40. PubMed ID: 11426526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.
    Bartlett NL; Petroni GR; Parker BA; Wagner ND; Gockerman JP; Omura GA; Canellos GP; Robert M; Johnson JL; Peterson BA
    Cancer; 2001 Jul; 92(2):207-17. PubMed ID: 11466671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination chemotherapy with cyclophosphamide, vincristine, adriamycin, and dexamethasone (CVAD) plus oral quinine and verapamil in patients with advanced breast cancer.
    Taylor CW; Dalton WS; Mosley K; Dorr RT; Salmon SE
    Breast Cancer Res Treat; 1997 Jan; 42(1):7-14. PubMed ID: 9116320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
    Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P
    Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparing CHOP, CHOP+HD-MTX,and BFM-90 regimens in the survival rate of children and adolescents with B cell non-Hodgkin's lymphoma].
    Sun XF; Su YS; Liu DG; Jiang WQ; He YJ; Lin TY; Huang HQ; Zhang L; Xia ZJ; Li YH; Zhou ZM; Chen XQ; Xia Y; Zhen ZJ; Guan ZZ
    Ai Zheng; 2004 Aug; 23(8):933-8. PubMed ID: 15301718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy and radiotherapy for stage I intermediate or high grade non-Hodgkin's lymphomas: results of a strategy that adapts radiotherapy dose to the response after chemotherapy.
    Krol AD; Berenschot HW; Doekharan D; Henzen-Logmans S; van der Holt B; van 't Veer MB
    Radiother Oncol; 2001 Mar; 58(3):251-5. PubMed ID: 11230885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas.
    Pan D; Qin J; Farber C; O'Brien J; Filippa D; Portlock CS
    Leuk Lymphoma; 2003 Jun; 44(6):967-71. PubMed ID: 12854895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized comparison of methotrexate dose and the addition of bleomycin to CHOP therapy for diffuse large cell lymphoma and other non-Hodgkin's lymphomas. Cancer and Leukemia Group B study 7851.
    Gottlieb AJ; Anderson JR; Ginsberg SJ; Bloomfield CD; Norton L; Barcos M; Peterson BA; Nissen N; Henderson ES; Holland JF
    Cancer; 1990 Nov; 66(9):1888-96. PubMed ID: 1699653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy.
    Sonneveld P; de Ridder M; van der Lelie H; Nieuwenhuis K; Schouten H; Mulder A; van Reijswoud I; Hop W; Lowenberg B
    J Clin Oncol; 1995 Oct; 13(10):2530-9. PubMed ID: 7595704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised multicentre trial of modified CHOP versus MCOP in patients aged 65 years and over with aggressive non-Hodgkin's lymphoma.
    Bessell EM; Burton A; Haynes AP; Glaholm J; Child JA; Cullen MH; Davies JM; Smith GM; Ellis IO; Jack A; Jones EL;
    Ann Oncol; 2003 Feb; 14(2):258-67. PubMed ID: 12562653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.